Free Newsletter
SPOTLIGHT: GSK's Arixtra losing to Rivaroxaban
Free newsletter via e-mail
Tools
A research report concludes that GlaxoSmithKline's anti-clotting drug Arixtra is losing ground to Rivaroxaban, made and marketed by Bayer Schering/Johnson & Johnson. Released by Decision Resources, the report cites Arixtra's need for close monitoring and its potential for serious side effects such as hemorrhage. Article
More stories about GlaxoSmithKline
Comments
By Anonymous | Posted 4:29pm | May 22, 2008
That's amazing given that rivaroxaban hasn't been launched yet. Regarding hemorrrage and close monitoring, things that are not associated with Arixtra, maybe there is some confusion with warfarin...? What utter rubbish!
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact
